Advancing non-small cell lung cancer treatment: the power of combination immunotherapies.

While the pembrolizumab plus favezelimab arm did not reach the efficacy bar, there was a notable trend toward improved ORR in the Tcell inf GEP non-low TMB high subgroup.

also in 2,083 other papers

At the second interim analysis (IA2), the median PFS with pembrolizumab with chemotherapy was 5.6 months compared to 5.5 months with placebo with chemotherapy, and the results did not reach statistical significance.

also in 61,332 other papers